I.G. Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

I.G. Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-7,150	Closed	-$1.04M	–	394
2017 Q1	$1.04M	Buy	7,150 +1,000	+16%	+$130K	0.01%	331
2016 Q4	$671K	Sell	6,150 -18,753	-75%	-$2.09M	﹤0.01%	362
2016 Q3	$3.02M	Buy	24,903 +1,185	+5%	+$160K	0.01%	455
2016 Q2	$3.35M	Buy	23,718 +1,200	+5%	+$177K	0.01%	448
2016 Q1	$2.94M	Buy	22,518 +2,336	+12%	+$291K	0.01%	446
2015 Q4	$2.84M	Buy	20,182 +108	+0.5%	+$15K	0.01%	432
2015 Q3	$2.67M	Buy	20,074 +6,167	+44%	+$1.06M	0.01%	422
2015 Q2	$2.45M	Hold	13,907	–	–	0.01%	469
2015 Q1	$2.4M	Sell	13,907 -2,702	-16%	-$464K	0.01%	468
2014 Q4	$2.72M	Sell	16,609 -600	-3%	-$99.6K	0.01%	434
2014 Q3	$2.76M	Buy	17,209 +1,800	+12%	+$277K	0.01%	417
2014 Q2	$2.27M	Buy	+15,409	New	+$2.14M	0.01%	462
2013 Q3	–	Sell	-13,900	Closed	-$955K	–	805
2013 Q2	$955K	Buy	+13,900	New	+$850K	﹤0.01%	568

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

I.G. Investment Management's JAZZ Position: Q2 2017 in Review

I.G. Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2017, closing a stake of 7,150 shares — an estimated $1.04M sold.

I.G. Investment Management first reported a position in JAZZ in Q2 2013 and held it in 13 quarters. The position peaked at $3.35M in Q2 2016. 319 funds tracked by Wall St. Rank hold JAZZ as of Q2 2017.

I.G. Investment Management reported no remaining Jazz Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
I.G. Investment Management sold 7,150 Jazz Pharmaceuticals shares in Q2 2017, an estimated $1.04M.
I.G. Investment Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 13 quarters.
I.G. Investment Management's Jazz Pharmaceuticals position peaked at $3.35M in Q2 2016.
319 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2017.

Based on I.G. Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.